NASDAQ:BPMC - Blueprint Medicines Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $89.54
  • Forecasted Upside: 64.56 %
  • Number of Analysts: 11
  • Breakdown:
  • 2 Sell Ratings
  • 3 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
▲ +4.48 (8.97%)

This chart shows the closing price for BPMC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Blueprint Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BPMC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BPMC

Analyst Price Target is $89.54
▲ +64.56% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Blueprint Medicines in the last 3 months. The average price target is $89.54, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 64.56% upside from the last price of $54.41.

This chart shows the closing price for BPMC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 11 contributing investment analysts is to hold stock in Blueprint Medicines. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 1 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 2 sell ratings

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/1/2022Stifel NicolausLower Price Target$98.00 ➝ $90.00Low
7/1/2022SVB LeerinkLower Price TargetMarket Perform$60.00 ➝ $56.00Low
6/27/2022Wells Fargo & CompanyInitiated CoverageUnderweight$40.00Low
6/14/2022Morgan StanleyLower Price TargetEqual Weight$92.00 ➝ $65.00Low
6/13/2022SVB LeerinkLower Price TargetMarket Perform$82.00 ➝ $60.00Low
6/10/2022HC WainwrightReiterated RatingBuy$100.00High
6/9/2022CitigroupDowngradeNeutral ➝ Sell$68.00 ➝ $41.00High
6/9/2022JMP SecuritiesReiterated RatingBuy$152.00High
6/1/2022Jefferies Financial GroupUpgradeHold ➝ Buy$88.00 ➝ $78.00High
5/18/2022Piper SandlerLower Price TargetNeutral$84.00 ➝ $65.00High
5/4/2022Robert W. BairdLower Price Target$123.00 ➝ $96.00Medium
4/13/2022CitigroupLower Price TargetNeutral$71.00 ➝ $68.00High
4/11/2022JMP SecuritiesReiterated RatingBuy$152.00Medium
3/4/2022Stifel NicolausBoost Price TargetBuy$100.00 ➝ $105.00Medium
2/28/2022WedbushReiterated RatingOutperform$126.00Low
2/28/2022CitigroupInitiated CoverageNeutral$71.00Low
2/17/2022SVB LeerinkLower Price TargetOutperform ➝ Market Perform$93.00 ➝ $82.00High
2/17/2022HC WainwrightLower Price TargetBuy$135.00 ➝ $100.00High
2/1/2022Morgan StanleyLower Price TargetEqual Weight$111.00 ➝ $92.00Medium
1/24/2022Stifel NicolausUpgradeHold ➝ Buy$120.00 ➝ $95.00Low
1/12/2022SVB LeerinkLower Price TargetOutperform$132.00 ➝ $120.00High
1/3/2022GuggenheimBoost Price Target$120.00 ➝ $122.00High
11/30/2021HC WainwrightReiterated RatingBuy$134.00High
11/30/2021JMP SecuritiesReiterated RatingBuy$151.00High
11/10/2021Raymond JamesBoost Price TargetStrong-Buy$122.00 ➝ $133.00Low
10/29/2021Morgan StanleyBoost Price TargetEqual Weight$96.00 ➝ $111.00High
7/30/2021Morgan StanleyLower Price TargetEqual Weight$101.00 ➝ $96.00Medium
6/17/2021WedbushLower Price TargetOutperform$136.00 ➝ $130.00High
6/17/2021SVB LeerinkBoost Price TargetOutperform$127.00 ➝ $137.00Low
6/17/2021Robert W. BairdBoost Price TargetOutperform$119.00 ➝ $123.00High
4/30/2021Morgan StanleyLower Price TargetEqual Weight$105.00 ➝ $101.00High
4/13/2021WedbushBoost Price TargetOutperform$119.00 ➝ $136.00Low
3/30/2021Credit Suisse GroupInitiated CoverageNeutral$100.00High
2/25/2021Morgan StanleyLower Price TargetEqual Weight$112.00 ➝ $105.00Low
2/18/2021HC WainwrightReiterated RatingBuyHigh
2/18/2021BarclaysBoost Price TargetEqual Weight$90.00 ➝ $95.00High
1/12/2021SVB LeerinkBoost Price TargetPositive ➝ Outperform$121.00 ➝ $127.00High
12/18/2020JMP SecuritiesBoost Price TargetOutperform$118.00 ➝ $152.00High
12/14/2020BMO Capital MarketsBoost Price TargetOutperform$113.00 ➝ $132.00Medium
12/2/2020Stifel NicolausInitiated CoverageHold$110.00High
11/2/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$90.00 ➝ $96.00High
11/2/2020HC WainwrightBoost Price TargetBuy$110.00 ➝ $135.00High
10/30/2020WedbushBoost Price Target$102.00 ➝ $115.00Low
10/30/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$112.00Low
10/29/2020Piper SandlerBoost Price TargetNeutral$77.00 ➝ $81.00Medium
10/16/2020Raymond JamesBoost Price TargetPositive ➝ Strong-Buy$106.00 ➝ $122.00Medium
10/13/2020Morgan StanleyBoost Price TargetOverweight$92.00 ➝ $100.00Low
9/23/2020SVB LeerinkBoost Price TargetOutperform$107.00 ➝ $121.00Medium
9/23/2020BMO Capital MarketsBoost Price TargetOutperform$105.00 ➝ $113.00Medium
9/23/2020BarclaysBoost Price TargetEqual Weight$77.00 ➝ $90.00Medium
9/22/2020Raymond JamesReiterated RatingBuyMedium
9/2/2020Raymond JamesReiterated RatingBuyHigh
7/31/2020HC WainwrightReiterated RatingBuyLow
7/27/2020SVB LeerinkBoost Price TargetOutperform$106.00 ➝ $107.00Medium
7/15/2020Morgan StanleyBoost Price TargetOverweight$88.00 ➝ $92.00Low
7/15/2020BarclaysReiterated RatingHold ➝ NeutralHigh
7/15/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$85.00 ➝ $95.00Medium
7/15/2020SVB LeerinkBoost Price TargetOutperform$105.00 ➝ $106.00High
7/15/2020HC WainwrightBoost Price TargetBuy$66.00 ➝ $110.00High
7/14/2020Robert W. BairdBoost Price TargetOutperform$90.00 ➝ $100.00High
7/14/2020Raymond JamesBoost Price TargetPositive ➝ Strong-Buy$95.00 ➝ $106.00High
6/8/2020Deutsche Bank AktiengesellschaftBoost Price TargetPositive ➝ Buy$70.00 ➝ $85.00High
6/8/2020BMO Capital MarketsBoost Price TargetOutperform$75.00 ➝ $111.00High
5/7/2020HC WainwrightReiterated RatingBuy$66.00Medium
5/4/2020BarclaysInitiated CoverageEqual Weight$59.00Low
4/30/2020Morgan StanleyLower Price TargetOverweight$103.00 ➝ $88.00Low
4/29/2020JMP SecuritiesLower Price TargetMarket Outperform$107.00 ➝ $103.00Medium
4/29/2020BMO Capital MarketsLower Price TargetOutperform$89.00 ➝ $75.00Medium
4/29/2020SVB LeerinkLower Price TargetOutperform$125.00 ➝ $105.00Medium
4/29/2020HC WainwrightLower Price TargetBuy$100.00 ➝ $66.00Medium
3/24/2020WedbushReiterated RatingOutperformHigh
3/17/2020SVB LeerinkBoost Price TargetOutperform ➝ Positive$116.00 ➝ $125.00Medium
3/17/2020BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$74.00 ➝ $89.00High
3/16/2020CowenInitiated CoverageBuyHigh
3/16/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$70.00High
2/18/2020Morgan StanleyLower Price TargetOverweight$108.00 ➝ $103.00Low
2/13/2020CowenReiterated RatingBuyHigh
1/27/2020BMO Capital MarketsInitiated CoverageMarket Perform$74.00Low
1/15/2020WedbushReiterated RatingPositive ➝ Outperform$141.00 ➝ $122.00Low
1/10/2020SVB LeerinkBoost Price Target$103.00 ➝ $120.00Low
1/9/2020HC WainwrightReiterated RatingBuyMedium
12/20/2019Piper Jaffray CompaniesLower Price TargetNeutral$85.00 ➝ $77.00Low
12/10/2019Deutsche Bank AktiengesellschaftLower Price TargetHold$75.00 ➝ $70.00Low
12/2/2019Deutsche Bank AktiengesellschaftInitiated CoverageSellMedium
11/7/2019HC WainwrightReiterated RatingBuy$100.00Low
11/6/2019Raymond JamesUpgradeOutperform ➝ Strong-Buy$106.00 ➝ $112.00Medium
10/28/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$110.00 ➝ $75.00High
10/22/2019JMP SecuritiesInitiated CoverageOutperform$106.00High
10/11/2019Morgan StanleyLower Price TargetOverweight$110.00 ➝ $109.00Low
10/3/2019HC WainwrightInitiated CoverageBuy$100.00High
9/30/2019CowenReiterated RatingBuyHigh
9/12/2019Raymond JamesUpgradeMarket Perform ➝ OutperformLow
9/9/2019Piper Jaffray CompaniesReiterated RatingHoldLow
9/9/2019CowenReiterated RatingBuyHigh
8/29/2019Piper Jaffray CompaniesInitiated CoverageNeutral$85.00Low
8/14/2019Raymond JamesReiterated RatingMkt Perform ➝ Market PerformHigh
7/18/2019Robert W. BairdInitiated CoverageOutperform$120.00Medium
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$110.00Medium
6/17/2019CowenReiterated RatingBuyLow
6/2/2019CowenReiterated RatingBuyHigh
5/23/2019The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$125.00High
4/3/2019Morgan StanleyInitiated CoverageOverweight$112.00Low
3/28/2019CowenReiterated RatingBuyHigh
2/26/2019WedbushReiterated RatingOutperformHigh
2/26/2019CowenReiterated RatingBuyMedium
1/7/2019WedbushReiterated RatingOutperform$103.00High
11/15/2018CowenReiterated RatingBuyHigh
10/22/2018WedbushReiterated RatingOutperform$101.00Medium
10/8/2018WedbushReiterated RatingOutperform$101.00Low
10/7/2018CowenReiterated RatingBuyLow
9/25/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$105.00Medium
9/18/2018GuggenheimInitiated CoverageBuy$102.00High
8/1/2018CowenReiterated RatingBuyHigh
6/4/2018JMP SecuritiesLower Price TargetMarket Outperform ➝ Buy$109.00 ➝ $103.00High
4/16/2018WedbushBoost Price TargetOutperform ➝ Outperform$98.00 ➝ $106.00High
4/16/2018JMP SecuritiesSet Price TargetBuy$97.00 ➝ $109.00High
2/21/2018CowenReiterated RatingBuyLow
12/11/2017The Goldman Sachs GroupBoost Price TargetBuy ➝ Buy$82.00 ➝ $99.00High
12/11/2017JMP SecuritiesBoost Price TargetOutperform$88.00 ➝ $97.00High
12/10/2017Raymond JamesSet Price TargetBuy$82.00High
11/10/2017CowenReiterated RatingBuyN/A
11/6/2017WedbushReiterated RatingOutperform$70.00 ➝ $82.00N/A
10/31/2017CowenReiterated RatingBuyN/A
10/23/2017Morgan StanleyBoost Price TargetOverweight$45.00 ➝ $78.00N/A
9/29/2017DA DavidsonInitiated CoverageBuy$90.00High
9/29/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$90.00High
9/20/2017The Goldman Sachs GroupReiterated RatingBuy$64.00 ➝ $79.00Low
9/5/2017Jefferies Financial GroupReiterated RatingBuy$56.00Medium
8/22/2017WedbushReiterated RatingOutperform$66.00High
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 24 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 2 very positive mentions
  • 24 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Blueprint Medicines logo
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $54.41
Low: $48.64
High: $54.42

50 Day Range

MA: $55.17
Low: $45.23
High: $64.50

52 Week Range

Now: $54.41
Low: $43.46
High: $117.86


1,061,270 shs

Average Volume

741,447 shs

Market Capitalization

$3.24 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Blueprint Medicines?

The following Wall Street analysts have issued stock ratings on Blueprint Medicines in the last year: Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Morgan Stanley, Piper Sandler, Raymond James, Robert W. Baird, Stifel Nicolaus,, SVB Leerink LLC, TheStreet, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for BPMC.

What is the current price target for Blueprint Medicines?

0 Wall Street analysts have set twelve-month price targets for Blueprint Medicines in the last year. Their average twelve-month price target is $89.54, suggesting a possible upside of 64.6%.
View the latest price targets for BPMC.

What is the current consensus analyst rating for Blueprint Medicines?

Blueprint Medicines currently has 2 sell ratings, 3 hold ratings, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BPMC, but not buy more shares or sell existing shares.
View the latest ratings for BPMC.

How do I contact Blueprint Medicines' investor relations team?

Blueprint Medicines' physical mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company's listed phone number is (617) 374-7580 and its investor relations email address is [email protected] The official website for Blueprint Medicines is Learn More about contacing Blueprint Medicines investor relations.